Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study to Assess the Safety, Tolerability and Antimalarial Activity of MMV533 Against Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers

NCT05205941 is registered in ClinicalTrials.gov with Medicines for Malaria Venture as lead sponsor.

NCT NCT05205941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05205941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study to Assess the Safety, Tolerability and Antimalarial Activity of MMV533 Against Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers
Lead sponsor
Medicines for Malaria Venture
Phase
Phase 1
Overall status
Completed
Start date
March 30, 2022
Completion date
September 2, 2022
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria